Avalo Therapeutics, Inc. reports developments for a clinical-stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases. Its recurring updates center on abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody evaluated in hidradenitis suppurativa, including LOTUS trial results, safety and efficacy disclosures, and program development plans.
Company news also covers financial results, investor presentations and conferences, equity compensation grants, public financing activity involving common stock and pre-funded warrants, and milestone obligations tied to the AlmataBio acquisition. These updates connect Avalo's clinical pipeline, capital needs, and governance actions to its public-company reporting cycle.
Avalo Therapeutics (AVTX) granted inducement stock options covering 101,600 common shares to three new employees on September 25, 2026.
The options have an exercise price of $15.47 per share, equal to the stock’s closing price on the grant date. The Compensation Committee approved the awards under Nasdaq Listing Rule 5635(c)(4). For each employee, 25% of the underlying shares vest on the first anniversary of their employment start date; the balance vests monthly over the following 36 months. Vesting requires continued service through the applicable dates. The awards are subject to Avalo’s 2025 Inducement Award Plan and award agreements.
Avalo Therapeutics (AVTX) will present new clinical data on its IL‑1β‑targeting therapies for hidradenitis suppurativa at the EADV Congress 2026 in Vienna, Austria from September 30–October 3, 2026.
The company will deliver a late‑breaker oral presentation on October 1, 2026 at 5:00pm CEST in Hall A, covering week‑16 efficacy and safety results of abdakibart (ABD) from the placebo‑controlled Phase 2 LOTUS trial, including IHS4 subgroup and lesion type ANdT analyses. A poster presentation on September 30, 2026 at 7:00am CEST in the ePoster Area (Inflammatory Skin Diseases – Part II) will report primary results of the same Phase 2 LOTUS trial. Avalo is advancing abdakibart into a Phase 3 registrational program in hidradenitis suppurativa and is also developing AVTX‑010, a long‑acting next‑generation anti‑IL‑1β monoclonal antibody.
Avalo Therapeutics (AVTX) granted inducement stock options to six new employees under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved nonstatutory options to purchase an aggregate of 78,000 common shares, granted on September 2, 2026, with an exercise price of $19.34 per share, equal to the closing share price on the grant date.
The options vest 25% on each employee’s one-year employment anniversary, with the remaining 75% vesting monthly over the following 36 months, subject to continued service. These awards were granted under Avalo’s 2025 Inducement Award Plan. The company continues to advance its lead anti-IL-1β antibody abdakibart into a planned phase 3 program in hidradenitis suppurativa and is also developing AVTX-010, a next-generation anti-IL-1β monoclonal antibody.
Avalo Therapeutics (AVTX) will participate in several healthcare investor conferences in September 2026, including fireside chats, 1x1 meetings and presentations. Events include Cantor on September 10, Morgan Stanley and H.C. Wainwright on September 16, and Stifel on September 24.
Live webcasts and replays, when available, will be accessible for at least 30 days in the Investors “News / Events” section of Avalo’s website.
Avalo Therapeutics (Nasdaq: AVTX) reported second quarter 2026 results and business updates, highlighting progress in its IL-1β-focused pipeline. The company plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa (HS) in the first half of 2027 and expects to submit an IND for AVTX-010, a long-acting next-generation anti-IL-1β antibody, in the same period.
Cash, cash equivalents and investments totaled $472.2 million as of June 30, 2026, which Avalo expects will fund operations into 2029. Q2 2026 research and development expenses were $23.4 million and general and administrative expenses were $8.1 million, leading to a net loss of $36.4 million or $0.83 per share. The company was added to the Russell 2000 and Russell 3000 Indexes and appointed Ron Philip to its Board of Directors.
Avalo Therapeutics (Nasdaq: AVTX) announced that CEO Dr. Garry Neil will speak on the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on July 29, 2026 at 10:30 a.m. ET. The company will also hold one-on-one investor meetings and provide live and archived webcasts via its investor relations website.
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, will participate in the Leerink Partners Therapeutics Forum.
Management plans to host one-on-one investor meetings on July 15, 2026, in Boston.
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech focused on IL-1β pathway therapies for immune-mediated inflammatory diseases, will join the Russell 2000 and Russell 3000 indexes.
Inclusion is effective after the close of U.S. equity markets on June 26, 2026, increasing exposure to index-based and benchmark-driven investors.
Avalo Therapeutics (Nasdaq: AVTX) appointed biopharma executive Ron Philip to its Board of Directors. He brings over 30 years of experience in commercial and strategic leadership, including roles at Orbital Therapeutics, Spark Therapeutics, Pfizer, and Wyeth.
The appointment follows positive Phase 2 LOTUS topline results for abdakibart in hidradenitis suppurativa and recent financing, as Avalo plans Phase 3 development and commercialization strategy.
Avalo Therapeutics (Nasdaq: AVTX) is advancing AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody for potential use in hidradenitis suppurativa (HS) and other inflammatory diseases.
AVTX-010 is engineered for extended dosing intervals and may enhance Avalo’s IL-1β-focused pipeline and intellectual property. An IND submission is planned for the first half of 2027.